| development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-cov-2. | the coronavirus disease 2019 (covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) threatens global public health. the development of a vaccine is urgently needed for the prevention and control of covid-19. here, we report the pilot-scale production of an inactivated sars-cov-2 vaccine candidate (bbibp-corv) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus maca ... | 2020 | 32778225 |